



Working **together** to build the LSHT ecosystem of today and tomorrow

Annual report on activities 2024

Table of contents

Table of contents	2
A message from our executives	3
Sector overview of life sciences in 2024	4
Our DNA	5
Assessment of the 2021-2024 strategic plan	6
Key actions	7
Our portfolio of projects	9
Our outreach	12
Effervescence	13
Decision-makers	15
Our team	16
Our allies	17
Committee participants	19



A message from our executives



Christine Lennon

Chairman of the Board

Actions and ambitions for the LSHT sector

Canada's life sciences and health technologies (LSHT) sector is strong, dynamic and growing, with 753 companies and more than 39,000 jobs in biopharmaceuticals, medical technologies and natural health products.* Internationally, our position is evolving. Between 2021 and 2024, Canada rose from 4th to 8th in the global rankings for artificial intelligence (AI), underscoring the urgency of accelerating innovation to maintain our competitiveness.

At Montréal InVivo, we actively contribute to this dynamic:

- **InVivo Talent** mobilized more than 220 students and 50 experts to prime the next generation of leaders in the sector.
- **Digital Transformation (OTN)** raised awareness among 23 companies and supported 14 of them in integrating digital solutions.

We aim to strengthen the sector's competitive edge by focusing on innovation, succession, and collaboration. These pillars are essential to rising to emerging challenges and maintaining our leadership role. By leveraging collective intelligence, we can propel the LSHT sector to even greater heights together.

* Source : [ministère de l'Économie, de l'Innovation et de l'Énergie.](#)



Stéphanie Doyle

President and CEO

It is with great pride and enthusiasm that I recently joined the Montréal InVivo team. Every day, I am inspired by the richness of our life sciences and health technologies (LSHT) ecosystem. For 2025 and beyond, I aspire to support its growth, strengthen strategic collaborations, and maximize our collective impact to benefit society as a whole.

Of course, the current context is marked by numerous uncertainties: geopolitical instability, economic constraints, pressure on supply chains, etc. These challenges weigh heavily on innovation and development, but our ecosystem continues to demonstrate its resilience. Thanks to its agility and ability to adapt, it continues to move forward, create, and transform constraints into opportunities.

Indeed, positive dynamics are emerging: strategic alliances are multiplying across Canada and internationally, consolidating our position. Concerted efforts to structure our sector, promote innovation, and accelerate the commercialization of technologies are bearing fruit. Montréal InVivo, through its role as a catalyst, benefits from strong commitment from stakeholders and a tremendous capacity for mobilization.

Now more than ever, we will rise to the challenges together. Driven by a spirit of collaboration, Quebec stands out for its proactive approach: here, we roll up our sleeves and get to work with determination to build a future full of innovation, health and hope.


Sector overview of life sciences in 2024

The life sciences and health technologies (LSHT) sector in Quebec stands out through its predominantly entrepreneurial fabric, consisting mainly of small and medium-sized enterprises (SMEs). This characteristic gives the sector great agility, sustained innovation capacity, and proximity to research and higher education ecosystems.

In this section, we present the most recent data on Quebec's life sciences sector, reflecting its economic vitality and evolution.

In 2022, the Ministère de l'Économie, de l'Innovation et de l'Énergie conducted a comprehensive census of companies and direct jobs related to life sciences. This update provides an accurate picture of the size, geographic distribution, and sub-sectors of activity, while highlighting the significant contributions of this strategic sector to the Quebec economy.

Number of SVTS companies by sub-sector and number of employees



Number of companies and jobs by sub-sector in 2022

Life sciences



Biopharmaceuticals
21,493 jobs



Medical technologies
15,643 jobs



Natural health products
2,201 jobs

TOTAL :
39,337 jobs

Our ADN

For nearly 20 years, Montréal InVivo has distinguished itself as a true leader in the LSHT sector. Our organization plays a leading role in identifying industry challenges and implementing initiatives to address them, acting as a catalyst to foster better interaction between companies and organizations in the sector. Our impact on the sector stems from our real, concrete commitment and our numerous projects, which integrate seamlessly with other economic development initiatives in the life sciences and health technologies sector in Quebec and Greater Montreal.

Our Positioning

We are recognized for our ability to rally support, our role as an independent and privileged interlocutor with public authorities, and our capacity to initiate and lead projects that are fundamental to the sector's development.

Our Mission

Montréal InVivo is a network for exchange, mobilization, and collaboration within the LSHT ecosystem. We provide leadership that brings together all stakeholders in Greater Montreal to strengthen the sector's growth, competitiveness, and influence.

Our Vision

Stand out with an innovative, collaborative, and sustainable ecosystem in life sciences and health technologies.

Our Values

Collaboration

Creativity

Leadership

Integrity

Excellence

Diversity

Our Actions

- Studies and analyses (business intelligence)
- Mobilization & networking
- Impactful projects
- Outreach
- Support for businesses and entrepreneurship



Review of the 2021-2024 Strategic Plan

Over the past three years, we have rolled out our strategic plan based on five key areas of focus: innovation, businesses, talent, positioning, and public acceptance. It is now time to take stock of the actions taken and the progress made for our life sciences and health technologies ecosystem.

	Area of Focus 1 Innovation	Area of Focus 2 Businesses	Area of Focus 3 Talent	Area of Focus 4 Positioning	Area of Focus 5 Public acceptance
Action Priorities	Contribute significantly to the adoption of technologies and practices developed in Quebec in LSHT.	Strengthen the creation, development, and growth of businesses in the sector.	Attract skilled and productive workers in a more targeted and active manner in order to support the sector in the long term.	Leverage the critical role of the LSHT sector in supporting the fight against the pandemic to make it an essential part of the economic recovery.	Raise public awareness about the impact of innovation in LSHT in Quebec.
Strategies	Promote and support initiatives aimed at stimulating the development and adoption of innovations in Quebec's healthcare network.	Development of an original service offering and strengthening of its capabilities in order to better equip and support entrepreneurs.	Diversify communication practices in order to better promote careers and raise the profile of the sector among young people.	Bring together Quebec stakeholders working to increase productivity and commercialize technologies, and co-develop an offering dedicated to the LSHT sector.	Launch and support new initiatives promoting public involvement in the innovation process in LSHT.
Activities carried out	<p>Rare diseases: Publication of the strategic plan for rare diseases in 2022.</p> <p>In 2023 :</p> <ul style="list-style-type: none"> Launch of the Mobilization table for rare diseases, bringing together more than 33 participants <p>In 2024, publication of a monitoring tool on new therapies indicated for rare conditions and on cell and gene therapies.</p> <p>Initiation of a project committee on value-based agreements in 2023</p> <p>AI and health:</p> <ul style="list-style-type: none"> 2022 – 2024: Balado Parcours IA en santé achieved in collaboration with ÉIAS (L'École de l'IA en santé) of the CHUM and Humanitéq. En 2023: Projet de Hub IA-santé Comparaison des meilleures pratiques et leçons apprises sur les centres d'accès aux données avec d'autres juridictions. Launch of a vitrine IA-Health (showcase) at the ALL-IN event and a web showcase on AI-health innovations. <p>Neurocognitive disorders and Alzheimer's disease: Distribution of a survey on healthcare professionals' perceptions of neurocognitive disorders in Quebec, with over 171 responses, including 10 categories of professionals.</p>	<p>Biosuccès: celebration of 10 years of BIOSUCCÈS at the Montréal InVivo Annual General Meeting in 2022.</p> <p>Momentum PI: 14 incubators and accelerators with which we collaborate.</p> <p>Partnership with the Conseil de l'innovation du Québec for a pilot project to refer businesses in the LSHT sector.</p> <p>Life Sciences Entrepreneurship Development Program: 7 cohorts launched since the program was created</p> <p>In April 2024, launch of the project on financing the LSHT sector: launch of the project committee, completion of the statistical study and interviews by Réseau Capital.</p>	<p>InVivo Talent: In 2024, we organized four events bringing together 220 participants and mobilized 35 panelists and experts to enrich the discussions.</p> <p>Continuum: The Continuum journey combines high-level training in AI and data science with practical mentoring in companies, in collaboration with partners such as IVADO, MILA, UdeM, ULaval, and CRIM. Participants have access to more than 20 expert mentors in data science.</p> <p>Vistasience: Collaboration with PharmabioDéveloppement to implement the Vistasience campaign, which promotes the SVTS sector.</p>	<p>Offensive Transformation Numérique (digital transformation offensive): 23 companies made aware and 14 companies supported thanks to the OTN program. In March 2024, an event was organized to raise awareness among companies about cybersecurity issues: "Cybersecurity in life sciences: protecting innovation, preventing threats" at Fasken.</p> <p>EFFERVESCENCE: three editions, more than 3,000 participants in 4 years, creation of competitions that promote the ecosystem in a broader sense (Raconte ta recherche en 180 secondes, Étoile, Pleins feux sur ta PME and start-up pitch competition).</p> <p>Study on the performance and attractiveness of North American LSHT hubs: the launch event was held on January 31, 2024.</p> <p>Development of pages on the sector's niches of excellence and files for international distribution.</p>	<p>Roadmap for the responsible development of an AI and health innovation hub: development in 2023.</p> <p>EDI project: analysis of the IDEA initiative and presentation at the Annual General Meeting held on May 28, 2024.</p>

Key actions

Every year, our project committees have set themselves apart through significant actions. Discover some of their achievements for 2024:

Invivo Talent

Talent Focus

Mandate

InVivo Talent aims to help students and young professionals integrate into the life sciences and health technologies sector. By highlighting the diversity of careers and creating opportunities to meet experts, the initiative supports the next generation in their professional development

Achievements

In 2024, InVivo Talent organized four key events to help students and young professionals better understand the ecosystem and opportunities available to them: academic-industry transition, sector discovery, entrepreneurial spirit, and research promotion. These events brought together more than 330 participants and 54 panelists and experts, helping to strengthen ties between the next generation and industry. In addition, a networking guide (in French) was created to equip students and enable them to engage more effectively with industry professionals.

→ [Access to the project](#)

→ [Download the networking guide](#)

Update of our AI - Health study

Innovation Focus

Mandate

The AI - Health study aims to provide an overview of the use of artificial intelligence in the life sciences and health technologies sector. The objective is to identify barriers to its adoption and explore potential solutions to maximize its impact.

Achievements

In 2024, several key milestones marked the progress of this study: a strategic meeting with the working committee, the official launch of the study, and interviews with key stakeholders in the field. These actions will provide a better understanding of the issues at stake and guide future recommendations.

→ [Access to the project](#)



Key actions

As every year, our project committees have distinguished themselves through significant actions. Discover some of their achievements for 2024:

Momentum PI

Business Focus

Mandate

Momentum PI aims to strengthen the quality of intellectual property (IP) for entrepreneurs in the life sciences and health technologies (LSHT) sector. Led by MAIN and promoted by Montréal InVivo for the sector, the program offers strategic support and grants to help companies develop and file their IP.

Achievements

In 2024, selection and administration processes were put in place with MAIN to identify and qualify eligible companies. Under Track 2, eight companies received a grant covering 75% of the costs of developing an IP strategy. Under Track 3, 15 companies received assistance covering 70% of the costs of filing IP applications.

→ [Access to the project](#)



AReNA

Positioning Focus

Mandate

AReNA aims to position Quebec as an international leader in the RNA therapy sector by promoting the sector and raising awareness of advances in the field among stakeholders. Montréal InVivo is responsible for the events component, helping to increase the visibility of Quebec initiatives locally, nationally, and internationally.

Achievements

In 2024, AReNA raised the profile of RNA therapies through a strategic partnership with CQDM, Axelys, and Montréal InVivo. Key actions included mapping key events and organizing a major event that brought together 136 participants in September 2024 in Montreal. The initiative was also present at RNA Canada ARN in Ottawa, FISQ in Quebec City, and CASTL's open house, with a total of 46 individual meetings and 10 strategic exchanges.

→ [Access to the project](#)




A changing ecosystem

At Montréal InVivo, our project committees are constantly growing and evolving to adapt to the sector's challenges and opportunities. Through their diversity and multidisciplinary approach, they shape strategic initiatives at every stage, from ideation to implementation.

In 2024, our portfolio of projects reflects more than ever the expertise and agility of our ecosystem.

Discover how these initiatives are transforming our industry and paving the way for new advances.

Notre portefeuille de projets



Innovation Focus

Rare diseases

Mandate

The Montréal InVivo Rare Diseases Project Committee was launched in 2019 with two main objectives:

1. To enable Quebec patients with rare diseases to have rapid and optimal access to therapeutic and diagnostic innovations.
2. To improve the competitiveness of Quebec's innovation ecosystem in order to attract investment and develop our skills.

Achievements

In 2024, the project reached several key milestones: first meeting of the co-chairs, session dedicated to EFFERVESCENCE 2024, sharing of the tool with the Minister's office and with INESSS.

→ [Access to the project](#)



Innovation Focus

Project for the early detection of major neurocognitive disorders (EDMND)


Mandate

Anticipate the arrival of innovations in neurocognitive disorders and prepare the Quebec healthcare system to integrate these advances to improve patient care.

Achievements

In 2024, the survey results were presented at the Barclay Family Symposium, followed by participation in the MSSS consultation day (March 18). A report is currently being finalized and will be published in 2025.

→ [Access to the project](#)





Value-based pricing agreements projects (OBA, outcome-based agreements)

Mandate

Initiate a discussion on the operationalization of value-based agreements in Quebec and propose a framework for implementing these agreements in Quebec that is resilient, sustainable, and can be extended to the rest of Canada in order to promote access to innovative treatments for Quebec patients.

Achievements

In 2024, project presentation meetings were organized with potential financial partners in Quebec and Canada. The search for funding for phase 1 confirmed four financial partners. Meetings with stakeholders were held, and a form was sent to pharmaceutical partners regarding candidate therapies.

→ [Access to the project](#)



Innovation Focus

Pro-Santé

Mandate

Develop and test innovative cross-sector solutions for the prevention, early detection, and management of chronic diseases, with an initial focus on obesity.

Achievements

Montréal InVivo has been integrated as a key partner in the Pro-Santé Steering Committee, a strategic partnership involving the FRQ, MEIE, MSSS, and Novo Nordisk. This initiative aims to create intersectoral partnerships to develop and test innovative solutions for the prevention and management of chronic diseases, with a particular focus on obesity.

→ [Access to the project](#)



Business Focus

Sustainable Development Initiative

Mandate

Raise awareness and mobilize players in the sector to amplify its social and environmental impact.

Achievements

This year, six inter-cluster meetings were organized, and a sustainable development resource page was created. Montréal InVivo joined Finance Montréal's Carbone 1 program and launched the second edition of the **"Spotlight on your SME"** contest, with a panel organized at EFFERVESCENCE in partnership with the ASPQ. A subcommittee for the creation of a cross-sector program was also set up, and a project was submitted to the Action Climat Québec program.

→ [Access to the project](#)



Positioning Focus

Economic data and indicators

Mandate

Update indicators of the economic value of the innovation chain and performance of the LSHT sector, in comparison with several North American jurisdictions.

Achievements

Follow-up and steering committee meetings for Study 2, with presentation of results: Quebec ranks 5th out of 21 overall and 10th in categories specific to our sector. A one-pager has also been posted online to present these results.

→ [Access to the project](#)



Positioning Focus

Financing chain study

Mandate

Conduct a study of the LSHT financing chain, identify deficiencies, and propose recommendations, while promoting meetings between entrepreneurs and investors.

Achievements

A project committee has been set up and Réseau Capital has been commissioned to carry out the study. Maps of LSHT financing stakeholders in Quebec have been drawn up and, along with the results of the study, will be published in 2025.

→ [Access to the project](#)



Positioning Focus

Digital transformation offensive

Mandate

The digital transformation offensive aimed to support life sciences and health technologies (LSHT) companies, particularly SMEs, in integrating digital technology into their business processes. The program was based on three complementary components: raising awareness through educational content (videos, testimonials, tutorials), referral to specialized support organizations, and support for the implementation of concrete projects thanks to the expertise of sector-specific committees. All developed in close collaboration with experts in the field.

Achievements

A total of 23 companies have been made aware of the challenges of digital transformation, and 14 of them have been supported in implementing projects adapted to their reality. This initiative has strengthened the sector's digital capabilities, while fostering synergies with specialized partners.

→ [Access to the project](#)

Our outreach

Our online presence

4,000

subscribers in 2024

25

events published on our website calendar

13,000

active users on our website

13,000

subscribers on LinkedIn

353

subscribers on YouTube



2024: an eventful year



January 25	The art of pitching: How to convince investors
January 31	Unveiling of the results of studies on sector indicators
February 29	B2B Thursdays: Round table on rare diseases
March 20	InVivo Talent: Academic Transition - Industry
March 27	Cybersecurity in life sciences: protect innovation, prevent threats
April 20 to May 1	EFFERVESCENCE 2024
April 30	InVivo Talent: Ecosystem discovery
May 28	Montréal InVivo's Annual General Meeting
September 12	Presentation of the RNA-based mobilizing project – AReNA
October 1	Information webinar on the Life Sciences Entrepreneurship Development Program (LSEDP)
October 16	InVivo Talent: Entrepreneurial approach
December 4	InVivo Talent: Research enhancement

The cluster in the news

- [Spotlight on RNA technology in La Press](#)
- [Multiple challenges for start-ups in La Presse](#)
- [Launch of the RNA cluster in Quebec in Les Affaires](#)

EFFERVESCENCE 2024

Visite website



The fifth edition of EFFERVESCENCE was held on April 30 and May 1, 2024 at Marché Bonsecours in Montreal, bringing together over 600 scientists, entrepreneurs, students, investors and professionals from the life sciences and health technologies sectors in Quebec and beyond.

With 630 registered participants and numerous international guests, this colorful showcased local and international innovations, and the talents of up-and-coming researchers and professionals.

Montréal InVivo is proud to play a leading role as a partner of this flagship event, co-created by a multidisciplinary organizing committee of 25 partners and supported by 30 financial partners. We were also fortunate to welcome a delegation of international journalists and scientists, who came to Montréal to discover the effervescence of our ecosystem.

630

participants

+300

organizations
present

+50

partners

10

captivating
lecturers

10

interactive
workshops

4

competitions



EFFERVESCENCE 2024 contests

The EFFERVESCENCE 2024 contest has once again confirmed its role as a catalyst in the life sciences and health technology ecosystem. Researchers, entrepreneurs, heads of start-ups and SMEs seized this unique opportunity to showcase their projects and accelerate their development.

“EFFERVESCENCE Stars”

CONTEST

The “EFFERVESCENCE Stars” contest has once again recognized three young researchers in Quebec who have distinguished themselves through their scientific contributions to the life sciences and health technologies sector. We are pleased to announce the three winners of the EFFERVESCENCE Stars contest!

Congratulations to **Vincent-Philippe Lavallée, Mike (Przemyslaw) Sapieha** and **Sylvie LeMay**!

“Spotlight on your SME”

CONTEST

The second edition of the “Spotlight on Your SME” contest was held this year at EFFERVESCENCE, highlighting SMEs committed to making the life sciences sector more sustainable and responsible. Congratulations to **Ananda Devices**, big winner of the 2024 edition!

Hosted by **Luc Sirois** and **Alain Bakayoko**, the competition gave representatives from three innovative SMEs the opportunity to take to the stage and present their respective organizations. **Ronan da Silva, PhD**, neuroscientific project manager at **Ananda Devices**, had the honour of winning the Quebec chief innovator prize

Congratulations also to **ChapteC** and **EcoloPharm • B Corp & Women Owned**, contest finalists.



EFFERVESCENCE Start-up Pitch COMPETITION

The EFFERVESCENCE Start-up Pitch Competition is back for its fourth edition. Congratulations to this year's winning companies:

1st prize in Biopharmaceutical & Biotechnology: Integrated Nanotherapeutics Inc. represented by **Chris Tam, PhD**

2nd prize in Biopharmaceutical & Biotechnology: Atorvia Health Technologies represented by **Jane Lapon**

Impact Award: CereCura Nanotherapeutics represented by **Louis-Philippe Bernier, PhD**

1st prize Medical Technology & Digital Health: Juno Technologies™ represented by **Nanette Sene**

2nd prize Medical Technology & Digital Health: vopemed represented by **Amy Lorincz**

“Tell us about your research in 180 seconds”

CONTEST

On the first day of EFFERVESCENCE, the “Tell us about your research in 180 seconds” contest was held.

This contest allowed young researchers to present their research work, and four of them won an award:

1st prize: Hiba Daghar of the CHUM Research Centre

2nd prize: Vrinda Nair of the Concordia University Research Centre

3rd prize: Camille Ingrand

«Coup de cœur» prize: Francis Lefebvre of Ventus Therapeutics

The decision-makers

4 board meetings in 2024

Members of the Board of Directors

François Bastien	Chairman of the Board	Medteq +
Cédric Bisson	Senior Investment Partner	Teralys Capital Inc.
Véronique Bougie	Chief Operating Officer	Semathera
Marie-Ève Côté	Lawyer, Partner	ROBIC
Marie-Ève Desrosiers	Interim President and Chief Executive Officer	CHUM
Dominique Bérubé	Vice-Rector, Research & Innovation	McGill University
Véronique Dugas	Operations Manager	CQDM
Carole Jabet	Scientific Director	FRQS
Yves Joannette	Deputy Vice-Rector, Research, Discovery, Creation, and Innovation	Université de Montréal
Alexandre Le Bouthillier	Partner	Linearis
Martin Leblanc	Co-Founder and Vice-Chair of the Board of Directors	CellCarta
Christine Lennon-Régimbal	Chief Executive Officer, Canada	Incyte Biosciences
Catherine Lunardi	President	GenAiz
Gordon McCauley	President and CEO	adMare BIOINNOVATIONS
Jacques Milette	Honorary Member	Membre honoraire
Maxime Pesant	Vice President, Private Investments and Impact Investments Life Sciences	FSTQ
Jean-Maurice Plourde	Honorary Member	Membre honoraire
Laurent Proulx	President and Chief Executive Officer CEO	Procure Alliance
Stefan Raos	Chief Executive Officer Canada	Moderna
Stéphanie Veyrun-Manetti	General Manager Specialty Care and Country Lead Canada	Sanofi
Matheus B Vieira	General Manager	Roche Diagnostics

Members who completed their term in 2024

Frank Béraud	Chief Executive Officer	Montréal InVivo
Dominique Bérubé	Vice-President, Research and Graduate Studies	McGill University
Diane Gosselin	President and CEO VP CA	CQDM
Rhian Touyz	Executive Director and Chief Scientific Officer	McGill University
Geneviève Guertin	Vice President, Investments – Life Sciences and Vice President, Investments – Fund Management (interim)	FSTQ
Gilbert Tordjman	Executive Director and Chief Scientific Officer	Research Institute McGill University Health Centre
Jean-François Fortin-Verreault	President and Chief Executive Officer	CIUSSS de l'Est de Montréal

Our Team

Driven by a spirit of innovation and cooperation, our team members are fully committed to advancing our projects and strengthening ties with industry stakeholders. Each member contributes their expertise and energy to build meaningful initiatives, constantly fueled by the desire to create a positive and lasting impact.

Our team underwent several changes in 2024. We said goodbye to Joëlle Chrisphonte, Malak Salah, Anne-Laure Gorget, and Robin Durand, whose contributions were invaluable to the development of our organization. **Their work and commitment have left a significant mark, and we thank them warmly for their contributions.**

In addition, Inès Desanlis left on parental leave, and we are delighted to announce that Anne-Abigail Fils-Aimé has stepped in to replace her during this period. We are very pleased to welcome Anne-Abigail to our team and look forward to benefiting from her expertise and energy.

At the same time, we have welcomed new talent that enriches our team with their expertise and vitality. Julie Fiol has joined our organization as Communications and Marketing Manager, while Yassine El Bakkouri now holds the position of Scientific Project Manager for AReNA. Tarek Hallal brings his expertise in innovation, Anne-Abigail Fils-Aimé is taking over the Momentum PI project, and Stéphanie Doyle will assume the role of CEO in early 2025.



Stéphanie Doyle
President and CEO



Claudie Noël
Senior Director – Operations



Farah Bendahmane
Senior Director – Strategic
Development and Partnerships



Josée Côté
Executive Assistant and Corporate
Affairs Coordinator



Alizée Gouronnec
Director – Impact and Business
Intelligence



Sophie Dallaire
Project Manager – Effervescence



Julie Fiol
Communications and Marketing
Manager



Yassine El Bakkouri
Scientific Project Manager – AReNA



Tarek Hallal
Project Manager – Innovations



Anne-Abigail Fils-Aimé
Project Manager – Momentum PI

Our allies

Our influence and impact are made possible by our rich network of partners and collaborators. From biopharmaceutical companies to health technology players, universities, research groups, support organizations, and various government agencies, we are privileged to have a diverse range of committed partners who share our vision.

Biopharmaceuticals

[Abbvie](#)
[AstraZeneca](#)
[Bausch Health](#)
[Biogen Canada Inc.](#)
[BioTalent](#)
[BMS \(Bristol Myers Squibb Canada\)](#)
[CellCarta](#)
[CIRION BioPharma Recherche Inc.](#)
[Eli Lilly](#)
[Gilead Sciences Canada Inc.](#)
[GSK](#)
[Incyte Biosciences](#)
[IQVIA](#)
[Janssen](#)
[Lundbeck](#)
[Merck Canada Inc.](#)
[Mispro Biotech Services Inc.](#)
[Moderna](#)
[Novo Nordisk Canada Inc.](#)
[PéripHarm](#)
[Pfizer](#)
[Roche Diagnostic](#)
[Sanofi](#)
[Takeda](#)
[Vertex Canada Inc](#)

Health technologies

[AmorChem II Ventures Inc.](#)
[Edwards Lifesciences](#)
[GenAlz](#)
[Insilico Meicine Canada Inc.](#)
[Linearis Labs](#)

Universities and research groups

[CERASP](#)
[CHUM - Centre hospitalier de l'Université de Montréal](#)
[CNRC](#)
[École de technologie supérieure \(ÉTS\)](#)
[FRQS](#)
[Génome Québec](#)
[IR-CUSM](#)
[Polytechnique MTL](#)
[Concordia University](#)
[Université de Montréal](#)
[McGill University](#)

Support organizations

[Amplitude Ventures](#)
[CBRE](#)
[Cité de la Biotech CQIB \(Ville Laval\)](#)
[CQDM](#)
[CTS-Santé](#)
[Fasken](#)
[Fonds de solidarité FTQ](#)
[Médicaments Novateurs \(IMC\)](#)
[MEDTEQ +/Consortium Medteq](#)
[Plakett Service Clinique](#)
[Teralys Capital \(Fonds d'Innovation\) inc.](#)

54
financial
partners

To all those
who contributed to
our efforts, thank
you for teaming
up with us.

Our allies

Sectoral clusters

[Aéro Montréal](#)
[AluQuébec](#)
[Cargo M](#)
[Ecotech Québec](#)
[Finance Montréal](#)
[GrappeM Mode](#)
[Life Science BC](#)
[Life Sciences Ontario \(LSO\)](#)
[Lyonbiopôle](#)
[Puzzle Medical Devices](#)
[TechnoMontréal](#)
[Bureau du Cinéma et de la télévision du Québec](#)
[Propulsion Québec](#)

Government levels

[Chambre de commerce du Montréal métropolitain \(CCMM\)](#)
[Conseil Emploi Métropole](#)
[Emploi-Québec](#)
[INESSS](#)
[Innovation, Sciences et Développement économique Canada / Gouvernement du Canada](#)
[Investissement Québec](#)
[Ministère de la Santé et des Services sociaux du Québec](#)
[Services Québec](#)

Universities and research groups

[Centre de recherche de l'institut universitaire en santé mentale de Québec \(in French\)](#)
[Centre de recherche du CHUM](#)
[Montreal Neurological Institute - Hospital \(the Neuro\)](#)
[Montreal Clinical Research Institute \(IRCM\)](#)
[IRICoR](#)
[Polytechnique Montréal](#)
[Université du Québec à Montréal](#)

Support organizations

[Bureau du cinéma et de la télévision du Québec](#)
[Cartagène](#)
[CATALIS Québec](#)
[John Molson Executive Centre](#)
[Clinical Trials Ontario](#)
[District 3 Centre d'innovation](#)
[Fondation de l'entrepreneurship](#)
[Hacking Health](#)
[Healthy Brains for Healthy Lives](#)
[TransMedtech Institut Living Lab](#)
[Le HUB Montréal](#)
[Les sociétés canadiennes de technologie des dispositifs médicaux \(MEDEC\)](#)
[Montréal International](#)
[Palais des congrès de Montréal](#)
[Pharmabio Développement \(in French\)](#)
[PROMPT \(in French\)](#)
[Québec International](#)
[RSSPQ](#)
[Sherbrooke Innopôle \(in French\)](#)
[TO Health!](#)

48
collaborators

Gouvernement of Canada

[Canada Economic Development for Quebec regions](#)
[CanExport funding for exporters, innovators, associations and communities](#)
[Innovation, Science and Economic Development Canada \(ISED\)](#)

Gouvernement of Quebec

[Conseil Emploi Métropole \(CEM\) \(in French\)](#)
[Emploi Québec – Services Québec](#)
[Ministère de l'Économie et de l'Innovation \(MEI\) \(in French\)](#)
[Secrétariat à la région métropolitaine \(in French\)](#)

Municipal level

[Communauté métropolitaine de Montréal \(CMM\) \(in French\)](#)
[Ville de Montréal](#)

9
government
levels

Committee participants

Over 200 committee participants

Adam Marsella
Novo Nordisk Canada, Inc.

Agnès Xenopoulos
Eli Lilly Canada

Alain Couture
GSK

Alain Madgin
Tactix

Alejandro Rodríguez Aguirre
CHUM

Alexia Liaud
Elas

Allison Wills
20Sense

Amélie Bergeron-Vachon
Écotech Québec

Amélie Bourdieu
Tremplin

Amy Lombard
CargoM

Anais Détolle
Numana

Angela Genge
Université de McGill

Anita Burgun
UdeS

Anmol Nagpal
Nospharma

Anne Nguyen
Conseil de l'Innovation du Québec

Anne-Marie Rivard
Roche Canada

Annie Blouin
Ministère de l'Économie, de l'Innovation et de l'Énergie

Annie-Kim Gilbert
MEDTEQ+

Antonin Caron
Roche Canada

Barbara Decelle
IVADO

Benoît Larose
BIOQuébec

Benoît Tousignant
Novo Nordisk

Brigitte Saint-Denis
Ministère de l'Économie, de l'Innovation et de l'Énergie

Camille Craig
CRCHUM

Carl-Éric Aubin
Institut TransMedTech

Carole Jabet
Fonds de recherche du Québec

Caroline Leblanc
Paraza Parma

Casandra Poitras
Conseils Zèbre Politique

Catherine Boivin
CORD

Catherine Lunardi
GENAIZ

Cécile Petitgand
DataLama

Cédric Bisson
Teralys

Célia Thouin Étudiante

Chaymaa Zouggari
Étudiante

Chloé Thibeault
Mmode

Christian Blouin
Patient partenaire

Christian Chabot
Patient partenaire

Claire Edrington
Novartis

Clara Scattolin
Étudiante

Claude LeDuc
RNA Technologies & Therapeutics

Claude Trépanier*
Numana

Cyril Bories
MSSS

Danielle Routhier
Ministère de la Santé et des Services sociaux

Darnly Dubois
Polytechnique

David Nolet
Conseil de l'innovation du Québec

Denis Laflamme
Takeda

Diana Iglesias
Génome Québec

Diane Brisson
Ecogene21

Dominique Grenier
Astrazeneca

Donald Allard
Bristol Myers Squibb

Donald Allard
BMS

Donald Vinh
Université de McGill

Eva Villalba
Coalition Priorité Cancer Québec

Ève Blanchet
Boehringer Ingelheim

Fares Antaki
UdeM

Florian Roulle
Finance Montréal

France Mignault
Gilead

François Bergeron
MEDTEQ+

François Bergeron
MEDTEQ+

François Laflamme
IQVIA

François Racine
AluQuébec

François Ravenelle
Inversago

Frédéric Leduc
EVAH corp

Gaëlle Bridon
Ministère de l'Économie, de l'Innovation et de l'Énergie

Gaëlle Bridon
Ministère de l'Économie, de l'Innovation et de l'Énergie

Gautier Berlemont
Mmode

Geneviève Latour
Propulsion Québec

Geneviève Pelletier
Association Québécoise des Pharmaciens Propriétaires

Geneviève Plamondon
INESSS

Genevieve Tousignant
Eisai

Ghernati Hamza
Montréal International

Gilles Duruflé
Réseau Capital

Hamza Ghernati
Réseau Capital

Hasna Rouighi
Ministère de la Santé et des Services sociaux

Hélène Vidot-Delerue
UQAM

Hermance Beaud
UQAM

Hyerin Kim
Étudiante

Imene Kouidmi
Astrazeneca

Inès Holzbaur
AmorChem

Isabelle Dubé-Côté
Écotech Québec

Isabelle Ducournau*
BCTQ

Isabelle Gagnon
Astra Zeneca

Jacques Michaud
Hôpital Sainte-Justine

Jade Falardeau
Ministère de la Santé et des Services sociaux

James Doyle
Modelis; DoyleBio

Jean Jutras
Astra Zeneca

Jean Lachaine
Faculté de Pharmacie de l'université

Jean-François Pariseau
Amplitude Ventures

Jean-Luc Fortier
Abbvie

Jeannine Burkhard
BIOQuébec

Jean-Sébastien Paquette
Symbiose Innovation

Jennifer Bessant
J&J

Jennifer Chan
Merck Canada

Jessica Forcillo
MSSS

Joanna Baraniewska
CIUSS du Centre-Ouest-de-l'Île-de-Montréal

John Kildea
Université de McGill

Jonathan Pratt
RQMO

Julian Duplan
Finance Montréal

Julie Couture
Ministère de la Santé et des Services sociaux

Julie Gauthier
Amgen

Julie Gregoire
CHUM

Julien Bertrand
Inversago

Justin Mallet
Roche Canada

Keith Woolrich
CUSM

Kimiaka Guerard
Axelys

Léa Guicheteau
Aéromontréal

Liliana Polcari
Biogen

Louis Verret
EVAH corp

Louis-Étienne Fortier
Investissement Québec

Louis-Pierre Charest
Centech

Luigi Lepanto
Université de Montréal

Lysane Martel
AluQuébec

Marc Pesant
CIUSSS du Nord-de-l'Île-de-Montréal

Marc Sébastien Verrault
Medtronic

Marc Vaucher
SCALE AI

Margaret Bywater-Ekgard
District 3

Maria Quinonez
AQPP

Marie-Claude Battista
UdeS

Marie-Hélène Bolduc
Dystrophie Musculaire Canada

Marie-Louise Temblay
AluQuébec

Mariem Abid
Marie-Paule Jeansonne

Mariem Abid
Forum IA

Marie-Soleil Gauthier
IRCM

Marine Kockmann
BCTQ

Mario Filion
bellus health

Martin Chenal
Neb

Martin Laroche
Bayer

Martine Carboneau
Novo Nordisk Canada, Inc.

Mathieu St-Arnaud Lavoie
Mmode

Maxime Dumais
Fonds de recherche du Québec

Maxime Pesant
Fonds de solidarité FTQ

Mélanie Caron
INESSS

Mélanie Langelier
Université de McGill

Meziane Silhadi
SQIAM

Meztli Arguello
Paraza Parma

Mikael Lemelin Brisebois
CHUM

Mounia Azzi
adMare Bioinnovations

Myène Levesque
Unité de soutien SSA Québec

Nadia Dubé
IRCM

Natalia Tourbina
CIUSSS du Centre-Sud-de-l'Île-de-Montréal

Nathalie Girard
Ministère de l'Économie, de l'Innovation et de l'Énergie

Nathalie Ouimet
CRCHUM

Nathalie Verreault
Roche Canada

Nathan Gueidon*
Aéromontréal

Nawal Kallida
Investissement Québec

Nguyen-Vi Mohamed
Innovitech

Nicolas Pilon
UQAM

Olivier Jérôme
Catalis

Oriane Morriet
Humaniteq

Paul L'Archevêque
CapCOGITO

Philippe Dessertenne*
Aéromontréal

Philippe Renaud
Alexion

Poppy Vineberg
Novo Nordisk Canada, Inc.

Prisca Bustamante
MITACS

Rachel Banville
Investissement Québec

Ranya El Masri
GSK

Raphaëlle St-Pierre
Centech

Roxanne Dault
UdeS

Sandra Favret
CIUSS du Nord-de-l'Île-de-Montréal

Sarah Gagnon
Conseil de l'innovation du Québec

Simon Pelletier
Réseau Capital

Sophie Larouche
Solutions cpo

Stéphanie Lacroix
Merck

Stephane Barakat
Abbvie

Stéphanie Doyle
Montréal International

Stéphanie Lacroix
Merck

Stephanie Levee
360 Public Affairs

Steve Labbé
Ministère de la Santé et des Services sociaux

Sylvain Baril
Janssen

Sylvain Clermont
Incyte

Sylvie Nichols
Edwards

Therence Bois
Valence Discovery

Thérèse Gagnon-Kugler
Vertex Pharmaceutical

Thomas Vignatou
Adoc Talent Management

Valérie Daigneault*
BCTQ

Valérie Guillot
Ministère de la Santé et des Services sociaux

Vincent Mooser
Université de McGill

Vincent Raymond
Pfizer

Xavier Abadie
SimforHealth

Xavier Linker
CQDM

Yasmine Lababou
Étudiante

Yves Couturier
Réseau 1 Québec

Yves Pastore
Hôpital Sainte-Justine

Ziad Nasreddine
Institut et Clinique MOCA

* n'est plus dans cette organisation



630 rue Sherbrooke Ouest bureau 460
Montréal, Québec H3A 1E4

514 987-9377



montreal-invivo.com